Relay Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Relay Therapeutics, Inc. (RLAY) reported Increase (Decrease) in Accounts Payable of -$993.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2024-11-06
- Relay Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2024-09-30 was -$4.30M.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2024-06-30 was $3.21M, a 14.38% increase year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2024-03-31 was $102.00K, a 92.71% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2023-12-31 was -$5.37M, a 373.21% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$2.39M, a 220.36% decline from fiscal 2022.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.99M, a 113.87% increase from fiscal 2021.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2021 was $930.00K.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2020 was -$410.00K, a 113.67% decline from fiscal 2019.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.09M derived: sum of 2 quarters · filed 2024-11-06 | -$993.00K 10-Q · filed 2024-11-06 | -$6.37M derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.31M 10-Q · filed 2024-08-06 | -$2.07M derived: sum of 3 quarters · filed 2024-08-06 | -$3.29M derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-03-31 | $102.00K 10-Q · filed 2024-05-02 | -$5.27M derived: sum of 2 quarters · filed 2024-05-02 | -$6.49M derived: sum of 3 quarters · filed 2024-11-06 | -$3.69M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-12-31 | -$5.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$6.60M derived: sum of 2 quarters · filed 2024-11-06 | -$3.79M derived: sum of 3 quarters · filed 2024-11-06 | -$2.39M 10-K · filed 2024-02-22 |
| 2023-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.58M derived: sum of 2 quarters · filed 2024-11-06 | $2.98M 10-Q · filed 2024-11-06 | $4.95M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.20M 10-Q · filed 2024-08-06 | $6.17M derived: sum of 3 quarters · filed 2024-08-06 | $10.80M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-02 | $3.37M derived: sum of 2 quarters · filed 2024-05-02 | $8.00M derived: sum of 3 quarters · filed 2024-05-02 | $4.61M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $6.60M derived: sum of 2 quarters · filed 2024-02-22 | $3.21M derived: sum of 3 quarters · filed 2024-02-22 | $1.99M 10-K · filed 2024-02-22 |
| 2022-09-30 | $4.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.25M derived: sum of 2 quarters · filed 2023-11-02 | $22.00K 10-Q · filed 2023-11-02 | $2.46M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$4.61M 10-Q · filed 2023-08-08 | -$2.18M derived: sum of 3 quarters · filed 2024-02-22 | -$2.81M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$1.22M 10-Q · filed 2023-05-04 | $1.21M derived: sum of 2 quarters · filed 2024-02-22 | $574.00K derived: sum of 3 quarters · filed 2024-02-22 | $518.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.80M derived: sum of 2 quarters · filed 2024-02-22 | $1.74M derived: sum of 3 quarters · filed 2024-02-22 | $930.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | -$636.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$692.00K derived: sum of 2 quarters · filed 2022-11-03 | -$1.50M 10-Q · filed 2022-11-03 | -$220.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$867.00K 10-Q · filed 2022-08-04 | $416.00K derived: sum of 3 quarters · filed 2023-02-23 | $2.77M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$811.00K 10-Q · filed 2022-05-05 | $472.00K derived: sum of 2 quarters · filed 2023-02-23 | $2.82M derived: sum of 3 quarters · filed 2023-02-23 | $1.12M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $3.63M derived: sum of 2 quarters · filed 2023-02-23 | $1.93M derived: sum of 3 quarters · filed 2023-02-23 | -$410.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $645.00K derived: sum of 2 quarters · filed 2021-11-10 | -$1.69M 10-Q · filed 2021-11-10 | $654.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$4.04M 10-Q · filed 2021-08-12 | -$1.70M derived: sum of 3 quarters · filed 2022-02-24 | -$1.57M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$2.34M 10-Q · filed 2021-05-13 | $9.00K derived: sum of 2 quarters · filed 2022-02-24 | $137.00K derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.48M derived: sum of 2 quarters · filed 2022-02-24 | $3.00M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $128.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $653.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $525.00K 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |